JP5376758B2 - テガフールの投与に起因する消化器毒性を軽減する方法 - Google Patents

テガフールの投与に起因する消化器毒性を軽減する方法 Download PDF

Info

Publication number
JP5376758B2
JP5376758B2 JP2006539166A JP2006539166A JP5376758B2 JP 5376758 B2 JP5376758 B2 JP 5376758B2 JP 2006539166 A JP2006539166 A JP 2006539166A JP 2006539166 A JP2006539166 A JP 2006539166A JP 5376758 B2 JP5376758 B2 JP 5376758B2
Authority
JP
Japan
Prior art keywords
tegafur
administered
pharmaceutically acceptable
acceptable salt
antitumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006539166A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007534634A (ja
JP2007534634A5 (enExample
Inventor
鳴夫 野村
健志 田原
弘 安部
潤 栗谷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of JP2007534634A publication Critical patent/JP2007534634A/ja
Publication of JP2007534634A5 publication Critical patent/JP2007534634A5/ja
Application granted granted Critical
Publication of JP5376758B2 publication Critical patent/JP5376758B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2006539166A 2004-04-29 2005-04-27 テガフールの投与に起因する消化器毒性を軽減する方法 Expired - Fee Related JP5376758B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56618004P 2004-04-29 2004-04-29
US60/566,180 2004-04-29
PCT/JP2005/008450 WO2005105086A1 (en) 2004-04-29 2005-04-27 Method for reducing gastrointestinal toxicity due to the administration of tegafur

Publications (3)

Publication Number Publication Date
JP2007534634A JP2007534634A (ja) 2007-11-29
JP2007534634A5 JP2007534634A5 (enExample) 2008-05-08
JP5376758B2 true JP5376758B2 (ja) 2013-12-25

Family

ID=35241420

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006539166A Expired - Fee Related JP5376758B2 (ja) 2004-04-29 2005-04-27 テガフールの投与に起因する消化器毒性を軽減する方法

Country Status (16)

Country Link
US (1) US20080166427A1 (enExample)
EP (1) EP1750703B1 (enExample)
JP (1) JP5376758B2 (enExample)
AT (1) ATE540679T1 (enExample)
AU (1) AU2005237364B2 (enExample)
CY (2) CY1112451T1 (enExample)
DK (1) DK1750703T3 (enExample)
ES (1) ES2378072T3 (enExample)
HR (1) HRP20120293T1 (enExample)
ME (1) ME01335B (enExample)
PL (1) PL1750703T3 (enExample)
PT (1) PT1750703E (enExample)
RS (1) RS52217B (enExample)
RU (1) RU2348409C2 (enExample)
SI (1) SI1750703T1 (enExample)
WO (1) WO2005105086A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010131769A1 (en) * 2009-05-13 2010-11-18 Taiho Pharmaceutical Co., Ltd. Treatment of diffuse-type gastric cancers using s-1 and cisplatin
BR112012000873A2 (pt) * 2009-07-17 2019-11-05 Myriad Genetics Inc método de dosar 5-fluorouracil em uma amostra de um paciente tratado com f-fu ou um pró-fármaco deste, método de tratar um paciente com 5-fluorouracil ou um pró-fármaco deste, método de processamento de uma amostra de sangue de um paciente tratado com um regime compreendendo 5-fluorouracil ou um pró-fármaco deste para um teste de 5-fluorouracil, método de processamento de uma amostra de sangue de um paciente tratado com um regime compreendendo 5-fluorouracil ou um pró-fármaco deste, composição, kit, kit de teste, conjunto de seringa de transferência
WO2011022174A1 (en) * 2009-08-21 2011-02-24 Myriad Genetics, Inc. Method of processing blood samples containing 5-fu
EP2422815A1 (en) 2010-08-18 2012-02-29 Grindeks, a joint stock company Pharmaceutical composition of tegafur and natural flavonoid derivative catechin for potentiating antitumour effect and for treating tumours
EP2422784A1 (en) 2010-08-18 2012-02-29 Grindeks, a joint stock company Composition of TEGAFUR, caffeic acid phenethyl ester (CAPE) and either catechin, kaempherol, myricetin or luteolin for potentiating antitumour effect and for treating tumours
EP2422848A1 (en) 2010-08-18 2012-02-29 Grindeks, a joint stock company Composition of tegafur, Indole-3-carbinol and either catechin, kaempherol, myricetin or luteolin for potentiating antitumour effect and for treating tumours
US10172839B2 (en) 2014-03-06 2019-01-08 University Of Southern California Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues
AU2015227009B2 (en) * 2014-03-06 2019-10-31 University Of Southern California Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues
AU2015238170B2 (en) * 2014-03-28 2019-08-15 L-Nutra Inc. Tyrosine kinase inhibitors for use in a method of treating cancer in association with a reduced caloric intake
JP6364546B2 (ja) * 2015-04-30 2018-07-25 大鵬薬品工業株式会社 抗腫瘍剤の副作用軽減剤
JP6439761B2 (ja) * 2016-08-09 2018-12-19 トヨタ自動車株式会社 ＮＯｘ吸蔵還元触媒の製造方法
CN106619689B (zh) * 2016-12-30 2018-05-01 陈晓华 一种用于治疗癌症的药物组合物、试剂盒及其应用
MX2022014094A (es) * 2020-05-19 2022-12-08 Cellix Bio Private Ltd Formulaciones farmaceuticas y sus preparaciones para el tratamiento del cancer.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3635946A (en) * 1969-07-22 1972-01-18 Solomon Aronovich Giller N1-(2'-furanidyl)-derivatives of 5-substituted uracils
DE3585869D1 (de) * 1984-10-30 1992-05-21 Otsuka Pharma Co Ltd Zusammensetzung zur steigerung der antikrebsaktivitaet einer antikrebsverbindung.
US5968914A (en) * 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
DE69003670T2 (de) * 1989-01-05 1994-01-27 Otsuka Pharma Co Ltd Nicht einspritzbares karzinostatisches mittel zur vorbeugung der entzündung durch 5-fluoruracil und verfahren zur behandlung von krebs.
WO1992021345A1 (en) * 1991-05-27 1992-12-10 Taiho Pharmaceutical Co., Ltd. Composition, method and kit for potentiating antitumor activity and for curing tumor
RU2198171C2 (ru) * 1998-10-12 2003-02-10 Леонидов Николай Борисович Новая кристаллическая модификация 5-фтор-1-(тетрагидро-2-фурил)-урацила и комплексные соединения на ее основе, обладающие противоопухолевым действием

Also Published As

Publication number Publication date
EP1750703B1 (en) 2012-01-11
US20080166427A1 (en) 2008-07-10
ES2378072T3 (es) 2012-04-04
CY2012014I1 (el) 2016-04-13
RU2006142101A (ru) 2008-06-20
CY1112451T1 (el) 2015-12-09
HRP20120293T1 (hr) 2012-04-30
ME01335B (me) 2013-12-20
RU2348409C2 (ru) 2009-03-10
DK1750703T3 (da) 2012-05-07
EP1750703A1 (en) 2007-02-14
ATE540679T1 (de) 2012-01-15
AU2005237364A1 (en) 2005-11-10
JP2007534634A (ja) 2007-11-29
PL1750703T3 (pl) 2012-05-31
WO2005105086A1 (en) 2005-11-10
EP1750703A4 (en) 2008-02-27
SI1750703T1 (sl) 2012-02-29
CY2012014I2 (el) 2016-04-13
PT1750703E (pt) 2012-02-23
AU2005237364B2 (en) 2010-07-08
RS52217B (sr) 2012-10-31

Similar Documents

Publication Publication Date Title
JP5376758B2 (ja) テガフールの投与に起因する消化器毒性を軽減する方法
EP1849470B1 (en) Anticancer drug containing alpha, alpha, alpha-trifluorothymidine and thymidine phosphorylase inhibitor
Ishikawa et al. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts
US10188656B2 (en) Methods of treatment of malignancies
US20200405737A1 (en) Combination therapy for treating malignancies
Overman et al. Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors
CN108601787A (zh) 用于治疗恶性肿瘤的组合疗法
US20130184232A1 (en) Methods for administering dpd inhibitors in combination with 5-fu and 5-fu prodrugs
US11571408B2 (en) Cancer treatment using docetaxel by controlling peak plasma levels
CN104159589A (zh) 肝脏状况的治疗
TW201912183A (zh) Hdac抑制劑與抗代謝藥劑組合用於癌症治療
Roviello et al. TAS-102 in gastric cancer: Development and perspectives of a new biochemically modulated fluroropyrimidine drug combination
JP2005513167A (ja) エポシロン誘導体と代謝拮抗剤からなる組合せ
WO2024238628A1 (en) Treatment of recurrent high-grade glioma or uveal melanoma (um) using a brain-penetrant protein arginine methyltransferase 5 (prmt5) inhibitor
WO2008109349A1 (en) Improved regimen for treating cancer with 5-fluorouracil, 5,10-methylenetetrahydrofolate and capecitabine
US8410096B2 (en) Antitumor agent, kit and method of treating cancer
KR20230031839A (ko) 암 치료에 사용하기 위한 벨바라페닙
CN114650816A (zh) 用于治疗胆管癌的包含帕比司他的联合疗法
Backus et al. Chemotherapeutic strategies for treatment of colorectal cancer: present and future developments
Tolcher et al. 463 POSTER Phase I study of sapacitabine, an oral nucleoside analogue, in patients with refractory solid tumors or lymphomas
Shirasaka et al. Preclinical and clinical practice of S-1 in Japan
HK40062087A (en) Combination therapies for use in treating cancer
Nief et al. 462 POSTER Research and identification of the polymorphisms of the thymidylate synthase gene in the human tumor cell lines panel of the National Cancer Institute (NCI)
Choy et al. 464 POSTER Pharmacokinetics of talotrexin (PT-523), a novel aminopterin analogue, in patients with non-small cell lung cancer
Budman Capecitabine: A Rationally Developed Anticancer Drug

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080321

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080321

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110920

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120904

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20121105

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130903

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130924

R150 Certificate of patent or registration of utility model

Ref document number: 5376758

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees